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Introduction: Calcium overload induced by chronic administration of the 
b-adrenoreceptor agonist, isoproterenol (IP), is used in animal to study the 
mechanisms of cardiac hypertrophy and failure.
Purpose: Time-dependent changes in myocardial perfusion, morphologic 
and functional parameters were assessed in rats in vivo using cardiac magnetic 
resonance imaging (MRI). Energy metabolism and nitric oxide (NO) pathway 
were evaluated in isolated perfused rat hearts following 7 days of treatment.
Methods: Male Wistar rats were infused for 7 days with isoproterenol 
(5 mg.kg-1 body weight.day-1, IsoP group, n=14) or vehicle (Control group, 
n=14).  MRI in vivo examinations were performed at day 1, 2 and 7 after 
pump implantation. Cine-MRI and arterial spin labeling technique were used 
to determine cardiac function and perfusion at all stages. For ex vivo studies, 
isolated hearts were perfused with a physiological buffer for 28 min before 
freeze-clamping for biochemical assays. High energy phosphate compounds 
and intracellular pH were followed using P-31 magnetic resonance spectros-
copy with simultaneous measurement of contractile function. NO pathway 
was evaluated by endothelial NO synthase expression and total nitrate concen-
tration (NOx).
Results: Left ventricular mass was increased in IsoP after 1 day (p<0.05). 
Diastolic wall thickness was increased in IsoP with a peak at day 2 and a 
return to basal value at day 7 (p<0.05). Myocardial blood À ow was increased 
at day 1 in IsoP group and returned to basal value between days 1 and 2 
(p<0.05).  After 7 days of treatment, cardiac function in explanted hearts 
was reduced by 36% in IsoP (p<0.05 vs Control). PCr/ATP ratio was lower 
(p<0.05) in IsoP (1.2±0.1) compared with Control (1.7±0.1). eNOS expression 
and NOx were increased in IsoP (p<0.05 vs Control).
Conclusions: IP increases myocardial perfusion and induces morphological 
changes in the heart within the ¿ rst 24 hours of administration. Cardiac hyper-
trophy and decreased cardiac function were associated with impaired phos-
phocreatine level and up-regulation of the NO pathway. These results could 
lead to a better understanding of the initial steps involved in cardiac hyper-
trophy and failure. 
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The angiotensin-converting enzyme inhibitor (ACE-I) delapril is used in 
combination with the third generation Ca2+ antagonist (CA) manidipine as 
a therapeutic option to control hypertension complicated by diabetes and 
microalbuminuria. In comparison with other ACE-Is, delaprilat, its active 
metabolite, binds with higher af¿ nity to the C-terminal enzymatic site (vs. the 
N-site) of ACE and has a higher cardiac af¿ nity. Manidipine lacks adverse 
effects of CAs with less catecholamines release known to contribute to cardiac 
remodeling. We studied the effects of a chronic treatment with the delapril-
manidipine combination on cardiac remodeling during heart failure (HF) 
using an experimental mouse model of  HF induced by left coronary artery 
ligation. Post-myocardial infarcted (PMI) mice were treated randomly for 4 
to 5 weeks with a non-hypotensive dose of delapril (6 mg/kg/day; PMI-D), 
manidipine (5 mg/kg/day; PMI-M), or delapril+manidipine (same doses; PMI-
DM). Kaplan-Meier analysis showed that treatments with delapril (±manidi-
pine) prevented PMI mortality. Manidipine had no bene¿ t. Echocardiographic 
analysis showed no major effects of the treatments on cardiac function, which 
may be inherent to the severe necrosis of the left ventricle (LV) in our MI 
model. Nevertheless, measurements of cell membrane capacitance with the 
patch-clamp technique showed that manidipine (±delapril) prevented LV 
myocytes hypertrophy (in pF; sham: 165±7; PMI: 255±9, PMI-D: 252±12, 
PMI-M: 181±12; PMI-DM: 220±9; n=27-48 cells). Electrophysiological ana-
lysis showed that the various drug treatments had no major effect neither on 
cellular action potentials nor on repolarizing outward K+ currents. However, 
preliminary results suggested that the drugs prevented MI effect on Ca2+ cur-
rents and Ca2+ handling. In conclusion, delapril and manidipine combine com-
plementary bene¿ cial effects on survival and cardiac remodeling after MI. We 
are currently investigating the cellular mechanisms involved.
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Cardiovascular events are a major cause of mortality in patients with end 
stage renal disease (ESRD). Recent data suggest that a multidisciplinary 
approach may improve patient’s care and survival. We present the data of a 
prospective observational pilot study conducted in patients refereed to the cli-
nical program of cardiac evaluation for ESRD (MONICARD) in our institu-
tion. The aim of our work is to investigate the ef¿ ciency of a dedicated cardiac 
evaluation program for ESRD patients.
Method: we recorded data from all patients referred between September 
the 1st and December the 31st 2010 in the MONICARD program. 
Results: 81 patients were referred: 39 patients before kidney transplantation 
(Pre-KT), 37 patients after kidney transplantation (Post-KT), and 5 patients 
without transplantation project. The mean age was 52.6±13. There were 
54 men and 27 women. Diabetic nephropathy was the leading cause (25 pts), 
followed by polycystic kidney (9 pts), IgA nephropathy (7 pts), and others 
glomerulonephritis (7 pts). 34 patients were under chronic dialysis: 28 Pre-KT 
and 1 Post-KT. Previous coronary artery disease was found in 14 patients 
and ECG abnormalities in 16 patients. Mean hemoglobin was 113±32 g/L. 
Echocardiography showed a mean LVEF of 64±8% and LV hypertrophy was 
found in 9 patients. Dobutamine stress echocardiography and/or myocar-
dial SPECT were performed in 41 patients (27 Pre-KT and 14 Post-KT) and 
showed signi¿ cant ischemia in 15 (37%) patients; 9 (33%) in Pre-KT and 6 
(43%) in Post-KT. Among them coronary angiography found signi¿ cant ste-
nosis in 3 (21%) patients who were all Pre-KT.
Conclusion: The low prevalence of signi¿ cant coronary stenosis in our 
population of ESRD patients with myocardial ischemia on non invasive 
testing may result from microvascular disease. Prospective evaluation of 
our patient’s outcomes and speci¿ c evaluation of myocardial microvascular 
disease may generate new diagnostic and therapeutics strategies in this high 
risk population.
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in Ca2+ sensitivity in subendocardial cells leading to loss of the endo-epicar-
dial gradient of myo¿ lament length-dependent activation. A reduced cardiac 
myosin-binding protein C phosphorylation and an increased troponin-I phos-
phorylation were observed in GRMD subendocardial cells. These changes 
were normalized by BK-treatment in GRMD dogs. In addition, the endo-
thelial nitric oxide synthase (eNOS) level was reduced in the LV myocar-
dium of placebo-treated GRMD dogs while that of BK-treated GRMD dogs 
was similar to control dogs. Thus, chronic treatment with BK normalizes LV 
contractile function in GRMD dogs by restoring the endo-epicardial gradient 
of the length-dependent activation, the eNOS expression and the sarcomeric 
protein phosphorylation. These data suggest that sarcomeric protein phospho-
rylation and NOS expression are potential mechanisms to treat cardiomyo-
pathy in DMD patients.
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In golden retriever dogs, a mutation in dystrophin gene leads to golden 
retriever muscular dystrophy (GRMD) presenting full spectrum of human 
pathology. Although some abnormalities in skeletal muscle and in heart are 
being recognized, little is known about vascular function in this model. To 
assess vascular endothelial function in this model and the effects of brady-
kinin (BK) that exerts a protective role in canine heart failure, 10 GRMD 
dogs with left ventricular dysfunction (indicated by a reduced fractional shor-
tening: 28±2% vs 38±2% in control dogs, p<0.001) and 8 control dogs were 
randomized to receive an infusion of saline (vehicle) or BK (1Pg/min) for 
4 weeks. Before treatment, acetylcholine (Ach, 3 g/kg) induced a smaller 
decrease in mean arterial pressure in GRMD (-18±2 mmHg) than in control 
dogs (-29±2 mmHg, p<0.01). After 4 weeks of treatment, this effect remained 
lower in vehicle-treated GRMD dogs while it was normalized in BK-treated 
GRMD, i.e., similar to control dogs. In isolated coronary artery rings, Ach 
(10-10-10-4M)-induced relaxation was nearly abolished in vehicle-treated 
GRMD dogs while in BK-treated GRMD, relaxation to Ach was restored 
and similar to that obtained in control dogs. This response was not modi-
¿ ed by indomethacin (indo, cyclooxygenase inhibitor) but was signi¿ cantly 
blunted by L-NA [nitric oxide synthase (NOS) inhibitor] or L-NA+indo. In 
addition, the endothelial NOS (eNOS) protein level and the cGMP content in 
the arterial tissue were signi¿ cantly lower in vehicle-treated GRMD while, 
in BK-treated GRMD, they were similar to those observed in control dogs. 
These data indicate that the dystrophin de¿ ciency-induced muscular dystrophy 
is associated with coronary and systemic endothelial dysfunction linked to an 
altered expression of eNOS. Chronic BK treatment normalizes endothelial 
dysfunction by upregulating eNOS expression suggesting BK-NO pathway is 
a potential target for treating vascular dysfunction in Duchenne patients 
0209
Impact of optimization of chronic heart failure treatment in improve-
ment of erectile function
Nadia Zoubeir [Orateur], F.Z. Wadrahmane, S. Abderazzak, A Bennis
CHU IBN ROCHD, CARDIOLOGIE, Casablanca, Maroc
Background: Chronic heart failure (CHF) and erectile dysfunction (ED) 
are two highly prevalent disorders that frequently occur concomitantly, and 
can signi¿ cantly and adversely affect quality of life.
Objective:To evaluate variations in sexual and erectile function in sub-
jects  with CHF after optimization of CHF treatment.
0241
TransRadial Approach and Subclavicular wired temporary pacemaker 
to increase safety of Alcohol septal ablation for obstructive hypertroph-
ic cardiomyopathy: the TRASA trial 
Jacques Quilici, Thomas Cuisset, Sebastien Ansaldi, Frederic Franceschi, 
Sebastien Prevot, Mathieu Pankert [Orateur], Jean Louis Bonnet
CHU TIMONE, cardiologie, pr bonnet, 10em etage, Marseille, France
Introduction: Alcool Septal Ablation (ASA) carries speci¿ c complica-
tions related to AV conduction problems, transient pacing and femoral access. 
Transfemoral temporary pacing catheters have several drawbacks inclu-
ding the risk of cardiac perforation, infection and the absence of any ¿ xation 
mechanism. Femoral artery catheterization resulted in a concomitant increase 
in bleedings and iatrogenic femoral artery injuries. The aim of our study was 
to evaluate feasibility of a less invasive management of ASA using transradial 
approach and subclavicular wired temporary pacemaker.
Method: We included 30 consecutive patients in our single center study. 
We used in all patients the right radial route. To avoid transfemoral temporary 
pacing, a subclavian bipolar active-¿ xation permanent pacing lead was posi-
tioned in the right ventricle with the tip screwed into the apical septum. The 
lead was stitched to the skin using the anchoring sleeve, connected to a deste-
rilized recuperation pacemaker for cost-effectiveness.
Results: 30 patients were included. The average gradient was 84.2+/-
29.4mmHg at the start of the procedure and 18.7+/-16 mm Hg at its comple-
tion. Overall, 12 of 30 patients (40%) developed right bundle branch block, 
and 6 (20%) developed complete AV block, requiring a permanent pacemaker 
implantation in 4 cases (13.3%). Without our approach allowing a safer and 
prolonged temporary pacing, the other two patients would probably have had 
de¿ nitive implantation for a ¿ nally transient AV block. No complication was 
observed during the hospital stay, neither access-site, nor stimulation lead 
related.    
Conclusions: Our study shows the feasibility and safety of a transradial 
approach and subclavicular wired temporary pacemaker. The reduction of peri-
procedural complications offered by this strategy inscribes in the less invasive 
logic of ASA, without increasing the cost and complexity of the procedure. 
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Due to a mutation of the dystrophin gene leading to loss of the protein 
in striated muscles, GRMD (Golden retriever muscular dystrophy) dogs 
reproduce the pathology and symptoms of the human Duchenne Muscular 
Dystrophy (DMD). A previous study has shown that chronic bradykinin (BK) 
infusion prevents the progression of heart failure in dogs. In the present study, 
we examined the effect of chronic infusion of BK on left ventricular (LV) 
function in GRMD dogs with reduced fractional shortening (28±2 vs 38±2% 
in GRMD and control dogs, respectively; p<0.001) and endo-epicardial gra-
dient of radial systolic velocity (1.3±0.1 vs 3.8±0.2 cm/s in GRMD and 
control dogs, respectively; p<0.001) measured by echocardiography. BK infu-
sion (1 Pg/min, 4 weeks) restored these parameters to levels similar to those 
measured in control dogs. The tension-pCa relationships obtained in isolated 
permeabilized subendocardial cells measured at 2 sarcomere lengths were 
rightward shifted in placebo-treated GRMD dogs compared to control myo-
cytes. This was associated with a decrease in maximum tension and a change 
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Objectives: To analyze the relation between the erectile dysfunction (ED) 
and the 6 minutes walk test (6MWT) in patients with chronic heart failure 
(CHF).
Methodes and results: The study population consisted of 75 men, aged 
35 to 74 years(mean age 61 years),with CHF and left ventricular dysfunction.
Erectile dysfunction was evaluated with the international index for erec-
tile function questionnaire-5(IIEF5).ED (IIEF-5, 21-5) was present in 42,6% 
(n=32), and no ED (IIEF-5,22-25) in 57,3%(n=43).
89% of patients with severe symptoms at the 6MWT had an ED, while only 
11% of patients without severe symptoms at the 6MWT present the ED (the 
difference was statistically signi¿ cant).
Patient with severe symptoms at the 6MWT  had more severe erectile 
dysfunction.
Conclusion: The prevalence of erectile dysfunction is higher in patient 
with severe symptoms at the 6MWT  compared to patients without severe 
symptoms at the 6MWT of similar demographic characteristics.
Erectile dysfunction affects patient quality of life, underlining the need for 
vigorous research of this condition and appropriate management.
Methods: 71 patients men (age range 45-72 years; mean age 63 years),with 
CHF and ED were asked to complete the International Index of Erectile 
Function IIEF5 before (at baseline) and 2 months after optimization of 
treatment.
Resultats: Among 36 patients studied;44,4% (n=16)have an optimal treat-
ment of CHF; versus  56,5%(n=20)have not, more than 57% of patients with 
optimal treatment of CHF showed signi¿ cant improvements on the 5 domains 
of the IIEF-5,compared to 13% of the patients without optimal treatment(the 
difference was statistically signi¿ cant).
Conclusion: The results of this study support the clinical impression that 
optimal treatment of CHF improves erectile function in patient with erectile 
dysfunction and CHF. 
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